HOME >> BIOLOGY >> NEWS
Memorial Sloan-Kettering Investigators

hat determines which patients respond to RA and which ones don't have identified a genetic difference between the two groups. APL patients who do well on RA treatment have leukemia that results from the fusion of two genes called PML and RAR-alpha (PML-RAR ), while the leukemia of patients who are resistant to RA is caused by a fusion of the genes PLZF and RAR-alpha (PLZF-RAR ).

To study these minute genetic differences further, Dr. Pandolfi and his colleagues developed two groups of mice: One group harbored the PML-RAR gene fusion, while a second group had the PLZF-RAR gene fusion. Both groups of mice developed APL similar to that seen in humans. In normal cells, certain proteins called transcription factors -- such as RAR -- turn on the expression of other genes with specific functions, such as controlling cell growth and maturation. Using advanced analytical techniques, Dr. Pandolfi's group showed that unlike RAR , proteins produced by the PML-RAR and PLZF-RAR gene fusions turned off, or "repressed," the expression of the cell's genes that normally prompt a cell to mature into a healthy, functioning white blood cell. Because these genes were turned off, the cells didn't mature, and leukemia developed. Moreover, the investigators found that PML-RAR and PLZF-RAR were acting as transcription repressors because of their ability to interact with other proteins. In PML- RAR , these interactions were broken apart by RA, while in PLZF-RAR they were insensitive to RA, explaining why retinoic acid works in some APL patients but not others.

Armed with this new knowledge, the MSKCC researchers set out to find ways to undo this chain of events. They knew that genetic material in a chromosome is tightly held together by proteins called histones. However, histones prevent individual gene expression. Previous studies of histones have shown that transcription repressors may work by favoring the place
'"/>

Contact: Kelli Stauning
stauningk@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
26-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Veterinary Memorial Fund transforms grief into promise
2. Andres Vazquez-Torres honored with 2004 Merck Irving S. Sigal Memorial Award
3. American Society for Microbiology honors Timothy Yahr with 2004 Merck Irving S. Sigal Memorial Award
4. Childrens Memorial, TGen announce partnership
5. Webcast of NSF Director Rita Colwells Chafee Memorial Lecture
6. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
7. Snapshot of new drug marks a major advance by Memorial Sloan-Kettering researchers
8. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
9. APS announces four 2004 Young Investigators awards
10. EMBO Young Investigators 2000 2002
11. Investigators use guilt-by-association strategy to track potential cancer causing genes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Memorial Sloan Kettering Investigators

(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... 2015  Analyst Report Issued by Small Cap IR. In 2011, ... planet-wide, transactions at merchants on the leading payment cards rose ... credit, debit, and prepaid cards reached 6.54 billion.  Eight million ... card usage in 2012, and credit and debit card fraud ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... studies for its newly developed Bruton,s tyrosine kinase ... been completed. The results of these preclinical evaluations ... Drug Administration. The feedback received from the Agency ... first-in-human study. Additional preclinical work is required to ...
(Date:2/27/2015)... A paper published today, " Financing ... in Science Translational Medicine, demonstrates the ... the risk associated with investing in the treatment ... of funding for developing so-called "orphan" drugs. ... between scientists at the National Center for Advancing ...
(Date:2/27/2015)... , Feb. 27, 2015 Research and Markets ... "Global Market Report of Trypsin" report to their offering. ... 9002-07-7) aims at providing comprehensive data on Trypsin globally and ... , North America , Latin ... close attention to Trypsin This report focuses on ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Global Market Report of Trypsin 2014-2018 2
Cached News: